EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 380 (1) , 191-200
Abstract
No abstract availableKeywords
Funding Information
- National High Technology Research and Development Program of China (2009AA02Z403, 2012AA02A501)
- National Key Basic Research Program of China (2011CB504300, 2011CB504305)
This publication has 49 references indexed in Scilit:
- Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinomaTherapeutics and Clinical Risk Management, 2014
- The cancer-virus curesNature Medicine, 2014
- Therapeutic Evaluation of Epstein-Barr Virus-encoded Latent Membrane Protein-1 Targeted DNAzyme for Treating of Nasopharyngeal CarcinomasMolecular Therapy, 2014
- Pathogenic role of Epstein–Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinomaCancer Letters, 2013
- The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC)Seminars in Cancer Biology, 2012
- Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma SurvivalJournal of Clinical Oncology, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- DNA damage signalling guards against activated oncogenes and tumour progressionOncogene, 2007
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- Epstein-Barr Virus and CancerClinical Cancer Research, 2004